Harris Associates
REGN icon

Harris Associates’s Regeneron Pharmaceuticals REGN Stock Holding History

Harris Associates’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-878
Closed -$631K – 147
2023
Q2 		$631K Sell
878
-1,008
-53% -$777K ﹤0.01% 130
2023
Q1 		$1.55M Sell
1,886
-87,753
-98% -$66.2M ﹤0.01% 122
2022
Q4 		$64.7M Sell
89,639
-98,537
-52% -$72.7M 0.13% 91
2022
Q3 		$130M Sell
188,176
-394,450
-68% -$248M 0.22% 79
2022
Q2 		$344M Sell
582,626
-510,391
-47% -$332M 0.55% 52
2022
Q1 		$763M Sell
1,093,017
-228,302
-17% -$144M 1.01% 28
2021
Q4 		$834M Sell
1,321,319
-4,977
-0.4% -$3.06M 1.3% 24
2021
Q3 		$803M Sell
1,326,296
-118,757
-8% -$73.7M 1.28% 26
2021
Q2 		$807M Buy
1,445,053
+411,475
+40% +$208M 1.29% 26
2021
Q1 		$489M Buy
1,033,578
+505,448
+96% +$246M 0.84% 44
2020
Q4 		$255M Sell
528,130
-138,165
-21% -$74.6M 0.49% 58
2020
Q3 		$373M Sell
666,295
-560,926
-46% -$340M 0.91% 37
2020
Q2 		$765M Sell
1,227,221
-1,089,797
-47% -$619M 1.86% 18
2020
Q1 		$1.13B Sell
2,317,018
-2,049,828
-47% -$846M 3.13% 7
2019
Q4 		$1.64B Buy
4,366,846
+225,394
+5% +$75.8M 2.91% 8
2019
Q3 		$1.15B Buy
4,141,452
+226,733
+6% +$67.1M 2.23% 13
2019
Q2 		$1.23B Buy
3,914,719
+1,247,748
+47% +$415M 2.25% 11
2019
Q1 		$1.1B Sell
2,666,971
-344,437
-11% -$142M 2.01% 12
2018
Q4 		$1.12B Sell
3,011,408
-162,236
-5% -$59.4M 2.27% 9
2018
Q3 		$1.28B Buy
3,173,644
+24,967
+0.8% +$9.5M 2.01% 13
2018
Q2 		$1.09B Buy
3,148,677
+1,448,644
+85% +$453M 1.76% 16
2018
Q1 		$585M Buy
+1,700,033
New +$591M 0.98% 38

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Harris Associates's REGN Position: Q3 2023 in Review

Harris Associates sold out of Regeneron Pharmaceuticals (REGN) in Q3 2023, closing a stake of 878 shares — an estimated $631K sold.

Harris Associates first reported a position in REGN in Q1 2018 and held it in 22 quarters. The position peaked at $1.64B in Q4 2019. 1,177 funds tracked by Wall St. Rank hold REGN as of Q3 2023.

  • Harris Associates reported no remaining Regeneron Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Harris Associates sold 878 Regeneron Pharmaceuticals shares in Q3 2023, an estimated $631K.
  • Harris Associates first reported a position in Regeneron Pharmaceuticals in Q1 2018 and held it in 22 quarters.
  • Harris Associates's Regeneron Pharmaceuticals position peaked at $1.64B in Q4 2019.
  • 1,177 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2023.

Based on Harris Associates's 13F filing for Q3 2023, filed 14 Nov 2023.